nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—ALB—acquired immunodeficiency syndrome	0.189	1	CbGaD
Fluoxetine—ORM1—Saquinavir—acquired immunodeficiency syndrome	0.0269	0.0461	CbGbCtD
Fluoxetine—CYP2B6—Efavirenz—acquired immunodeficiency syndrome	0.0179	0.0307	CbGbCtD
Fluoxetine—CYP2B6—Nevirapine—acquired immunodeficiency syndrome	0.0169	0.0289	CbGbCtD
Fluoxetine—CYP2B6—Lopinavir—acquired immunodeficiency syndrome	0.0169	0.0289	CbGbCtD
Fluoxetine—CYP2B6—Amprenavir—acquired immunodeficiency syndrome	0.0153	0.0261	CbGbCtD
Fluoxetine—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.0133	0.0228	CbGbCtD
Fluoxetine—CYP2B6—Nelfinavir—acquired immunodeficiency syndrome	0.0128	0.0219	CbGbCtD
Fluoxetine—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.012	0.0206	CbGbCtD
Fluoxetine—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.012	0.0206	CbGbCtD
Fluoxetine—CYP2B6—Ritonavir—acquired immunodeficiency syndrome	0.0116	0.0198	CbGbCtD
Fluoxetine—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.0114	0.0195	CbGbCtD
Fluoxetine—ALB—Saquinavir—acquired immunodeficiency syndrome	0.0113	0.0194	CbGbCtD
Fluoxetine—ALB—Zidovudine—acquired immunodeficiency syndrome	0.0109	0.0186	CbGbCtD
Fluoxetine—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.0107	0.0184	CbGbCtD
Fluoxetine—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0105	0.018	CbGbCtD
Fluoxetine—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.0104	0.0178	CbGbCtD
Fluoxetine—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.0101	0.0173	CbGbCtD
Fluoxetine—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.00989	0.0169	CbGbCtD
Fluoxetine—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.00989	0.0169	CbGbCtD
Fluoxetine—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.0097	0.0166	CbGbCtD
Fluoxetine—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.0097	0.0166	CbGbCtD
Fluoxetine—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.00948	0.0162	CbGbCtD
Fluoxetine—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.00911	0.0156	CbGbCtD
Fluoxetine—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.00911	0.0156	CbGbCtD
Fluoxetine—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.00895	0.0153	CbGbCtD
Fluoxetine—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.00891	0.0153	CbGbCtD
Fluoxetine—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.00891	0.0153	CbGbCtD
Fluoxetine—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.00867	0.0148	CbGbCtD
Fluoxetine—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.00865	0.0148	CbGbCtD
Fluoxetine—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.00837	0.0143	CbGbCtD
Fluoxetine—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.00815	0.014	CbGbCtD
Fluoxetine—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.00815	0.014	CbGbCtD
Fluoxetine—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.00813	0.0139	CbGbCtD
Fluoxetine—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.00806	0.0138	CbGbCtD
Fluoxetine—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.00806	0.0138	CbGbCtD
Fluoxetine—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.00782	0.0134	CbGbCtD
Fluoxetine—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0075	0.0128	CbGbCtD
Fluoxetine—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.00737	0.0126	CbGbCtD
Fluoxetine—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.00737	0.0126	CbGbCtD
Fluoxetine—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.00735	0.0126	CbGbCtD
Fluoxetine—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.00735	0.0126	CbGbCtD
Fluoxetine—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.00705	0.0121	CbGbCtD
Fluoxetine—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.00696	0.0119	CbGbCtD
Fluoxetine—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.00678	0.0116	CbGbCtD
Fluoxetine—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.00676	0.0116	CbGbCtD
Fluoxetine—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.00675	0.0116	CbGbCtD
Fluoxetine—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.00656	0.0112	CbGbCtD
Fluoxetine—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.00636	0.0109	CbGbCtD
Fluoxetine—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.00618	0.0106	CbGbCtD
Fluoxetine—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.00611	0.0105	CbGbCtD
Fluoxetine—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.00611	0.0105	CbGbCtD
Fluoxetine—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.00593	0.0102	CbGbCtD
Fluoxetine—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.00593	0.0102	CbGbCtD
Fluoxetine—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.00586	0.01	CbGbCtD
Fluoxetine—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00568	0.00974	CbGbCtD
Fluoxetine—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.00559	0.00957	CbGbCtD
Fluoxetine—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.00559	0.00957	CbGbCtD
Fluoxetine—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00551	0.00944	CbGbCtD
Fluoxetine—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00518	0.00888	CbGbCtD
Fluoxetine—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00518	0.00888	CbGbCtD
Fluoxetine—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00469	0.00803	CbGbCtD
Fluoxetine—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00469	0.00803	CbGbCtD
Fluoxetine—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.0044	0.00753	CbGbCtD
Fluoxetine—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00405	0.00693	CbGbCtD
Fluoxetine—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00393	0.00673	CbGbCtD
Fluoxetine—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00355	0.00608	CbGbCtD
Fluoxetine—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00355	0.00608	CbGbCtD
Fluoxetine—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00341	0.00583	CbGbCtD
Fluoxetine—ORM1—saliva—acquired immunodeficiency syndrome	0.0029	0.0875	CbGeAlD
Fluoxetine—SLC6A2—nerve—acquired immunodeficiency syndrome	0.00125	0.0378	CbGeAlD
Fluoxetine—SLC6A4—blood plasma—acquired immunodeficiency syndrome	0.00108	0.0324	CbGeAlD
Fluoxetine—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.000893	0.0269	CbGeAlD
Fluoxetine—HTR2A—nerve—acquired immunodeficiency syndrome	0.000754	0.0227	CbGeAlD
Fluoxetine—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.000729	0.022	CbGeAlD
Fluoxetine—CYP3A5—blood plasma—acquired immunodeficiency syndrome	0.000703	0.0212	CbGeAlD
Fluoxetine—CYP2B6—blood plasma—acquired immunodeficiency syndrome	0.000699	0.021	CbGeAlD
Fluoxetine—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.000692	0.0208	CbGeAlD
Fluoxetine—HTR2A—endothelium—acquired immunodeficiency syndrome	0.000642	0.0193	CbGeAlD
Fluoxetine—HTR2A—blood plasma—acquired immunodeficiency syndrome	0.00057	0.0172	CbGeAlD
Fluoxetine—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000528	0.0159	CbGeAlD
Fluoxetine—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000519	0.0156	CbGeAlD
Fluoxetine—ORM1—blood—acquired immunodeficiency syndrome	0.000463	0.0139	CbGeAlD
Fluoxetine—ORM1—bone marrow—acquired immunodeficiency syndrome	0.000448	0.0135	CbGeAlD
Fluoxetine—ORM1—spinal cord—acquired immunodeficiency syndrome	0.000446	0.0134	CbGeAlD
Fluoxetine—SLC6A4—digestive system—acquired immunodeficiency syndrome	0.000414	0.0125	CbGeAlD
Fluoxetine—ORM1—lung—acquired immunodeficiency syndrome	0.000406	0.0122	CbGeAlD
Fluoxetine—HTR2C—spinal cord—acquired immunodeficiency syndrome	0.000401	0.0121	CbGeAlD
Fluoxetine—SLC6A4—blood—acquired immunodeficiency syndrome	0.000395	0.0119	CbGeAlD
Fluoxetine—SIGMAR1—blood—acquired immunodeficiency syndrome	0.000392	0.0118	CbGeAlD
Fluoxetine—SLC6A4—spinal cord—acquired immunodeficiency syndrome	0.00038	0.0114	CbGeAlD
Fluoxetine—SIGMAR1—bone marrow—acquired immunodeficiency syndrome	0.000379	0.0114	CbGeAlD
Fluoxetine—SIGMAR1—spinal cord—acquired immunodeficiency syndrome	0.000378	0.0114	CbGeAlD
Fluoxetine—ORM1—nervous system—acquired immunodeficiency syndrome	0.000376	0.0113	CbGeAlD
Fluoxetine—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000374	0.0112	CbGeAlD
Fluoxetine—SIGMAR1—vagina—acquired immunodeficiency syndrome	0.000363	0.0109	CbGeAlD
Fluoxetine—ORM1—central nervous system—acquired immunodeficiency syndrome	0.000362	0.0109	CbGeAlD
Fluoxetine—SLC6A4—lung—acquired immunodeficiency syndrome	0.000346	0.0104	CbGeAlD
Fluoxetine—SIGMAR1—lung—acquired immunodeficiency syndrome	0.000344	0.0103	CbGeAlD
Fluoxetine—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000343	0.0103	CbGeAlD
Fluoxetine—HTR2C—nervous system—acquired immunodeficiency syndrome	0.000338	0.0102	CbGeAlD
Fluoxetine—CYP2B6—skin of body—acquired immunodeficiency syndrome	0.000336	0.0101	CbGeAlD
Fluoxetine—CYP2C19—blood—acquired immunodeficiency syndrome	0.000327	0.00985	CbGeAlD
Fluoxetine—HTR2C—central nervous system—acquired immunodeficiency syndrome	0.000325	0.0098	CbGeAlD
Fluoxetine—SLC6A4—nervous system—acquired immunodeficiency syndrome	0.00032	0.00965	CbGeAlD
Fluoxetine—HTR2A—retina—acquired immunodeficiency syndrome	0.000312	0.0094	CbGeAlD
Fluoxetine—SLC6A4—central nervous system—acquired immunodeficiency syndrome	0.000308	0.00929	CbGeAlD
Fluoxetine—SLC6A2—lung—acquired immunodeficiency syndrome	0.000305	0.00917	CbGeAlD
Fluoxetine—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000303	0.00913	CbGeAlD
Fluoxetine—SLC6A2—nervous system—acquired immunodeficiency syndrome	0.000282	0.00849	CbGeAlD
Fluoxetine—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.00028	0.00844	CbGeAlD
Fluoxetine—ORM1—lymph node—acquired immunodeficiency syndrome	0.000278	0.00836	CbGeAlD
Fluoxetine—CYP2B6—lymphoid tissue—acquired immunodeficiency syndrome	0.000272	0.00819	CbGeAlD
Fluoxetine—SLC6A2—central nervous system—acquired immunodeficiency syndrome	0.000272	0.00818	CbGeAlD
Fluoxetine—CYP3A5—digestive system—acquired immunodeficiency syndrome	0.00027	0.00814	CbGeAlD
Fluoxetine—CYP2B6—digestive system—acquired immunodeficiency syndrome	0.000269	0.00809	CbGeAlD
Fluoxetine—CYP1A2—blood—acquired immunodeficiency syndrome	0.000267	0.00804	CbGeAlD
Fluoxetine—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000266	0.00801	CbGeAlD
Fluoxetine—HTR2C—brain—acquired immunodeficiency syndrome	0.000258	0.00778	CbGeAlD
Fluoxetine—CYP3A5—blood—acquired immunodeficiency syndrome	0.000258	0.00776	CbGeAlD
Fluoxetine—CYP2B6—blood—acquired immunodeficiency syndrome	0.000256	0.00771	CbGeAlD
Fluoxetine—CYP2C9—blood—acquired immunodeficiency syndrome	0.000254	0.00763	CbGeAlD
Fluoxetine—ALB—brain—acquired immunodeficiency syndrome	0.000252	0.00759	CbGeAlD
Fluoxetine—SLC6A4—brain—acquired immunodeficiency syndrome	0.000245	0.00737	CbGeAlD
Fluoxetine—ALB—lymph node—acquired immunodeficiency syndrome	0.000244	0.00733	CbGeAlD
Fluoxetine—SIGMAR1—brain—acquired immunodeficiency syndrome	0.000243	0.00732	CbGeAlD
Fluoxetine—CYP3A5—vagina—acquired immunodeficiency syndrome	0.000239	0.00719	CbGeAlD
Fluoxetine—CYP2B6—vagina—acquired immunodeficiency syndrome	0.000237	0.00715	CbGeAlD
Fluoxetine—SIGMAR1—lymph node—acquired immunodeficiency syndrome	0.000235	0.00708	CbGeAlD
Fluoxetine—CYP1A2—lung—acquired immunodeficiency syndrome	0.000234	0.00705	CbGeAlD
Fluoxetine—CYP3A5—lung—acquired immunodeficiency syndrome	0.000226	0.0068	CbGeAlD
Fluoxetine—CYP2B6—lung—acquired immunodeficiency syndrome	0.000224	0.00676	CbGeAlD
Fluoxetine—HTR2A—digestive system—acquired immunodeficiency syndrome	0.000219	0.0066	CbGeAlD
Fluoxetine—SLC6A2—brain—acquired immunodeficiency syndrome	0.000216	0.00649	CbGeAlD
Fluoxetine—HTR2A—blood—acquired immunodeficiency syndrome	0.000209	0.00629	CbGeAlD
Fluoxetine—SLC6A2—lymph node—acquired immunodeficiency syndrome	0.000208	0.00627	CbGeAlD
Fluoxetine—CYP2B6—nervous system—acquired immunodeficiency syndrome	0.000208	0.00626	CbGeAlD
Fluoxetine—ABCB1—retina—acquired immunodeficiency syndrome	0.000205	0.00616	CbGeAlD
Fluoxetine—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000203	0.00611	CbGeAlD
Fluoxetine—HTR2A—spinal cord—acquired immunodeficiency syndrome	0.000201	0.00606	CbGeAlD
Fluoxetine—CYP2B6—central nervous system—acquired immunodeficiency syndrome	0.0002	0.00602	CbGeAlD
Fluoxetine—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.0002	0.00601	CbGeAlD
Fluoxetine—HTR2A—vagina—acquired immunodeficiency syndrome	0.000194	0.00583	CbGeAlD
Fluoxetine—CYP3A4—blood—acquired immunodeficiency syndrome	0.000193	0.00582	CbGeAlD
Fluoxetine—CYP2D6—blood—acquired immunodeficiency syndrome	0.00019	0.00573	CbGeAlD
Fluoxetine—HTR2A—lung—acquired immunodeficiency syndrome	0.000183	0.00551	CbGeAlD
Fluoxetine—HTR2A—nervous system—acquired immunodeficiency syndrome	0.00017	0.0051	CbGeAlD
Fluoxetine—HTR2A—central nervous system—acquired immunodeficiency syndrome	0.000163	0.00491	CbGeAlD
Fluoxetine—CYP2B6—brain—acquired immunodeficiency syndrome	0.000159	0.00478	CbGeAlD
Fluoxetine—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000157	0.00473	CbGeAlD
Fluoxetine—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000154	0.00465	CbGeAlD
Fluoxetine—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000151	0.00455	CbGeAlD
Fluoxetine—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000149	0.00448	CbGeAlD
Fluoxetine—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000145	0.00438	CbGeAlD
Fluoxetine—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000144	0.00432	CbGeAlD
Fluoxetine—ABCB1—blood—acquired immunodeficiency syndrome	0.000137	0.00412	CbGeAlD
Fluoxetine—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000132	0.00399	CbGeAlD
Fluoxetine—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000132	0.00397	CbGeAlD
Fluoxetine—HTR2A—brain—acquired immunodeficiency syndrome	0.00013	0.0039	CbGeAlD
Fluoxetine—ABCB1—vagina—acquired immunodeficiency syndrome	0.000127	0.00382	CbGeAlD
Fluoxetine—ABCB1—lung—acquired immunodeficiency syndrome	0.00012	0.00361	CbGeAlD
Fluoxetine—CYP2D6—brain—acquired immunodeficiency syndrome	0.000118	0.00355	CbGeAlD
Fluoxetine—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000111	0.00334	CbGeAlD
Fluoxetine—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000107	0.00322	CbGeAlD
Fluoxetine—ABCB1—brain—acquired immunodeficiency syndrome	8.49e-05	0.00256	CbGeAlD
Fluoxetine—ABCB1—lymph node—acquired immunodeficiency syndrome	8.21e-05	0.00247	CbGeAlD
Fluoxetine—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	4.76e-05	0.000246	CcSEcCtD
Fluoxetine—Myalgia—Ritonavir—acquired immunodeficiency syndrome	4.76e-05	0.000246	CcSEcCtD
Fluoxetine—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	4.75e-05	0.000245	CcSEcCtD
Fluoxetine—Anaemia—Lamivudine—acquired immunodeficiency syndrome	4.75e-05	0.000245	CcSEcCtD
Fluoxetine—Anxiety—Ritonavir—acquired immunodeficiency syndrome	4.75e-05	0.000245	CcSEcCtD
Fluoxetine—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	4.73e-05	0.000245	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	4.73e-05	0.000244	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	4.71e-05	0.000244	CcSEcCtD
Fluoxetine—Pruritus—Abacavir—acquired immunodeficiency syndrome	4.71e-05	0.000243	CcSEcCtD
Fluoxetine—Fatigue—Indinavir—acquired immunodeficiency syndrome	4.71e-05	0.000243	CcSEcCtD
Fluoxetine—Anorexia—Delavirdine—acquired immunodeficiency syndrome	4.71e-05	0.000243	CcSEcCtD
Fluoxetine—Discomfort—Ritonavir—acquired immunodeficiency syndrome	4.7e-05	0.000243	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	4.7e-05	0.000243	CcSEcCtD
Fluoxetine—Cough—Saquinavir—acquired immunodeficiency syndrome	4.7e-05	0.000243	CcSEcCtD
Fluoxetine—Angioedema—Lamivudine—acquired immunodeficiency syndrome	4.69e-05	0.000243	CcSEcCtD
Fluoxetine—Constipation—Indinavir—acquired immunodeficiency syndrome	4.67e-05	0.000241	CcSEcCtD
Fluoxetine—Pain—Indinavir—acquired immunodeficiency syndrome	4.67e-05	0.000241	CcSEcCtD
Fluoxetine—Insomnia—Efavirenz—acquired immunodeficiency syndrome	4.67e-05	0.000241	CcSEcCtD
Fluoxetine—Urticaria—Zidovudine—acquired immunodeficiency syndrome	4.66e-05	0.000241	CcSEcCtD
Fluoxetine—Convulsion—Saquinavir—acquired immunodeficiency syndrome	4.66e-05	0.000241	CcSEcCtD
Fluoxetine—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	4.66e-05	0.000241	CcSEcCtD
Fluoxetine—Hypertension—Saquinavir—acquired immunodeficiency syndrome	4.65e-05	0.00024	CcSEcCtD
Fluoxetine—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	4.64e-05	0.00024	CcSEcCtD
Fluoxetine—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	4.64e-05	0.00024	CcSEcCtD
Fluoxetine—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	4.64e-05	0.00024	CcSEcCtD
Fluoxetine—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	4.63e-05	0.000239	CcSEcCtD
Fluoxetine—Malaise—Lamivudine—acquired immunodeficiency syndrome	4.63e-05	0.000239	CcSEcCtD
Fluoxetine—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	4.62e-05	0.000239	CcSEcCtD
Fluoxetine—Nausea—Didanosine—acquired immunodeficiency syndrome	4.62e-05	0.000239	CcSEcCtD
Fluoxetine—Vertigo—Lamivudine—acquired immunodeficiency syndrome	4.61e-05	0.000238	CcSEcCtD
Fluoxetine—Hypotension—Delavirdine—acquired immunodeficiency syndrome	4.61e-05	0.000238	CcSEcCtD
Fluoxetine—Syncope—Lamivudine—acquired immunodeficiency syndrome	4.61e-05	0.000238	CcSEcCtD
Fluoxetine—Confusional state—Ritonavir—acquired immunodeficiency syndrome	4.6e-05	0.000238	CcSEcCtD
Fluoxetine—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	4.6e-05	0.000238	CcSEcCtD
Fluoxetine—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	4.6e-05	0.000238	CcSEcCtD
Fluoxetine—Somnolence—Efavirenz—acquired immunodeficiency syndrome	4.59e-05	0.000237	CcSEcCtD
Fluoxetine—Chest pain—Saquinavir—acquired immunodeficiency syndrome	4.58e-05	0.000237	CcSEcCtD
Fluoxetine—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	4.58e-05	0.000237	CcSEcCtD
Fluoxetine—Myalgia—Saquinavir—acquired immunodeficiency syndrome	4.58e-05	0.000237	CcSEcCtD
Fluoxetine—Anxiety—Saquinavir—acquired immunodeficiency syndrome	4.57e-05	0.000236	CcSEcCtD
Fluoxetine—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	4.55e-05	0.000235	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	4.55e-05	0.000235	CcSEcCtD
Fluoxetine—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	4.54e-05	0.000235	CcSEcCtD
Fluoxetine—Discomfort—Saquinavir—acquired immunodeficiency syndrome	4.53e-05	0.000234	CcSEcCtD
Fluoxetine—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	4.51e-05	0.000233	CcSEcCtD
Fluoxetine—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	4.5e-05	0.000233	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	4.5e-05	0.000232	CcSEcCtD
Fluoxetine—Shock—Ritonavir—acquired immunodeficiency syndrome	4.49e-05	0.000232	CcSEcCtD
Fluoxetine—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	4.48e-05	0.000232	CcSEcCtD
Fluoxetine—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	4.48e-05	0.000232	CcSEcCtD
Fluoxetine—Cough—Lamivudine—acquired immunodeficiency syndrome	4.48e-05	0.000232	CcSEcCtD
Fluoxetine—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	4.48e-05	0.000232	CcSEcCtD
Fluoxetine—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	4.47e-05	0.000231	CcSEcCtD
Fluoxetine—Dizziness—Stavudine—acquired immunodeficiency syndrome	4.47e-05	0.000231	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	4.46e-05	0.000231	CcSEcCtD
Fluoxetine—Insomnia—Delavirdine—acquired immunodeficiency syndrome	4.46e-05	0.000231	CcSEcCtD
Fluoxetine—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	4.45e-05	0.00023	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	4.45e-05	0.00023	CcSEcCtD
Fluoxetine—Convulsion—Lamivudine—acquired immunodeficiency syndrome	4.45e-05	0.00023	CcSEcCtD
Fluoxetine—Vomiting—Nevirapine—acquired immunodeficiency syndrome	4.45e-05	0.00023	CcSEcCtD
Fluoxetine—Fatigue—Efavirenz—acquired immunodeficiency syndrome	4.45e-05	0.00023	CcSEcCtD
Fluoxetine—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	4.43e-05	0.000229	CcSEcCtD
Fluoxetine—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	4.43e-05	0.000229	CcSEcCtD
Fluoxetine—Confusional state—Saquinavir—acquired immunodeficiency syndrome	4.43e-05	0.000229	CcSEcCtD
Fluoxetine—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	4.41e-05	0.000228	CcSEcCtD
Fluoxetine—Pain—Efavirenz—acquired immunodeficiency syndrome	4.41e-05	0.000228	CcSEcCtD
Fluoxetine—Constipation—Efavirenz—acquired immunodeficiency syndrome	4.41e-05	0.000228	CcSEcCtD
Fluoxetine—Rash—Nevirapine—acquired immunodeficiency syndrome	4.41e-05	0.000228	CcSEcCtD
Fluoxetine—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	4.41e-05	0.000228	CcSEcCtD
Fluoxetine—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	4.4e-05	0.000227	CcSEcCtD
Fluoxetine—Dizziness—Abacavir—acquired immunodeficiency syndrome	4.4e-05	0.000227	CcSEcCtD
Fluoxetine—Somnolence—Delavirdine—acquired immunodeficiency syndrome	4.39e-05	0.000227	CcSEcCtD
Fluoxetine—Headache—Nevirapine—acquired immunodeficiency syndrome	4.38e-05	0.000227	CcSEcCtD
Fluoxetine—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	4.37e-05	0.000226	CcSEcCtD
Fluoxetine—Chest pain—Lamivudine—acquired immunodeficiency syndrome	4.37e-05	0.000226	CcSEcCtD
Fluoxetine—Myalgia—Lamivudine—acquired immunodeficiency syndrome	4.37e-05	0.000226	CcSEcCtD
Fluoxetine—Infection—Saquinavir—acquired immunodeficiency syndrome	4.36e-05	0.000226	CcSEcCtD
Fluoxetine—Anxiety—Lamivudine—acquired immunodeficiency syndrome	4.36e-05	0.000225	CcSEcCtD
Fluoxetine—Anorexia—Ritonavir—acquired immunodeficiency syndrome	4.35e-05	0.000225	CcSEcCtD
Fluoxetine—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	4.34e-05	0.000225	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	4.34e-05	0.000224	CcSEcCtD
Fluoxetine—Urticaria—Indinavir—acquired immunodeficiency syndrome	4.34e-05	0.000224	CcSEcCtD
Fluoxetine—Shock—Saquinavir—acquired immunodeficiency syndrome	4.32e-05	0.000223	CcSEcCtD
Fluoxetine—Discomfort—Lamivudine—acquired immunodeficiency syndrome	4.32e-05	0.000223	CcSEcCtD
Fluoxetine—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	4.32e-05	0.000223	CcSEcCtD
Fluoxetine—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	4.32e-05	0.000223	CcSEcCtD
Fluoxetine—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	4.31e-05	0.000223	CcSEcCtD
Fluoxetine—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	4.3e-05	0.000222	CcSEcCtD
Fluoxetine—Vomiting—Stavudine—acquired immunodeficiency syndrome	4.29e-05	0.000222	CcSEcCtD
Fluoxetine—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	4.29e-05	0.000222	CcSEcCtD
Fluoxetine—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	4.28e-05	0.000221	CcSEcCtD
Fluoxetine—Rash—Nelfinavir—acquired immunodeficiency syndrome	4.27e-05	0.000221	CcSEcCtD
Fluoxetine—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	4.27e-05	0.000221	CcSEcCtD
Fluoxetine—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	4.27e-05	0.000221	CcSEcCtD
Fluoxetine—Hypotension—Ritonavir—acquired immunodeficiency syndrome	4.27e-05	0.00022	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	4.26e-05	0.00022	CcSEcCtD
Fluoxetine—Rash—Stavudine—acquired immunodeficiency syndrome	4.26e-05	0.00022	CcSEcCtD
Fluoxetine—Fatigue—Delavirdine—acquired immunodeficiency syndrome	4.26e-05	0.00022	CcSEcCtD
Fluoxetine—Dermatitis—Stavudine—acquired immunodeficiency syndrome	4.26e-05	0.00022	CcSEcCtD
Fluoxetine—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	4.25e-05	0.00022	CcSEcCtD
Fluoxetine—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	4.25e-05	0.000219	CcSEcCtD
Fluoxetine—Headache—Nelfinavir—acquired immunodeficiency syndrome	4.24e-05	0.000219	CcSEcCtD
Fluoxetine—Headache—Stavudine—acquired immunodeficiency syndrome	4.23e-05	0.000219	CcSEcCtD
Fluoxetine—Vomiting—Abacavir—acquired immunodeficiency syndrome	4.23e-05	0.000219	CcSEcCtD
Fluoxetine—Confusional state—Lamivudine—acquired immunodeficiency syndrome	4.23e-05	0.000218	CcSEcCtD
Fluoxetine—Pain—Delavirdine—acquired immunodeficiency syndrome	4.22e-05	0.000218	CcSEcCtD
Fluoxetine—Constipation—Delavirdine—acquired immunodeficiency syndrome	4.22e-05	0.000218	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	4.22e-05	0.000218	CcSEcCtD
Fluoxetine—Asthenia—Zidovudine—acquired immunodeficiency syndrome	4.21e-05	0.000218	CcSEcCtD
Fluoxetine—Rash—Abacavir—acquired immunodeficiency syndrome	4.2e-05	0.000217	CcSEcCtD
Fluoxetine—Dermatitis—Abacavir—acquired immunodeficiency syndrome	4.19e-05	0.000217	CcSEcCtD
Fluoxetine—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	4.19e-05	0.000217	CcSEcCtD
Fluoxetine—Anorexia—Saquinavir—acquired immunodeficiency syndrome	4.19e-05	0.000216	CcSEcCtD
Fluoxetine—Headache—Abacavir—acquired immunodeficiency syndrome	4.17e-05	0.000215	CcSEcCtD
Fluoxetine—Infection—Lamivudine—acquired immunodeficiency syndrome	4.16e-05	0.000215	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	4.16e-05	0.000215	CcSEcCtD
Fluoxetine—Nausea—Nevirapine—acquired immunodeficiency syndrome	4.16e-05	0.000215	CcSEcCtD
Fluoxetine—Pruritus—Zidovudine—acquired immunodeficiency syndrome	4.15e-05	0.000215	CcSEcCtD
Fluoxetine—Insomnia—Ritonavir—acquired immunodeficiency syndrome	4.13e-05	0.000213	CcSEcCtD
Fluoxetine—Shock—Lamivudine—acquired immunodeficiency syndrome	4.12e-05	0.000213	CcSEcCtD
Fluoxetine—Hypotension—Saquinavir—acquired immunodeficiency syndrome	4.11e-05	0.000212	CcSEcCtD
Fluoxetine—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	4.1e-05	0.000212	CcSEcCtD
Fluoxetine—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	4.1e-05	0.000212	CcSEcCtD
Fluoxetine—Urticaria—Efavirenz—acquired immunodeficiency syndrome	4.1e-05	0.000212	CcSEcCtD
Fluoxetine—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	4.08e-05	0.000211	CcSEcCtD
Fluoxetine—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	4.08e-05	0.000211	CcSEcCtD
Fluoxetine—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	4.07e-05	0.00021	CcSEcCtD
Fluoxetine—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	4.07e-05	0.00021	CcSEcCtD
Fluoxetine—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	4.07e-05	0.00021	CcSEcCtD
Fluoxetine—Somnolence—Ritonavir—acquired immunodeficiency syndrome	4.06e-05	0.00021	CcSEcCtD
Fluoxetine—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	4.05e-05	0.000209	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	4.04e-05	0.000209	CcSEcCtD
Fluoxetine—Nausea—Nelfinavir—acquired immunodeficiency syndrome	4.02e-05	0.000208	CcSEcCtD
Fluoxetine—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	4.02e-05	0.000208	CcSEcCtD
Fluoxetine—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	4.02e-05	0.000208	CcSEcCtD
Fluoxetine—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	4.02e-05	0.000208	CcSEcCtD
Fluoxetine—Nausea—Stavudine—acquired immunodeficiency syndrome	4.01e-05	0.000207	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	4e-05	0.000207	CcSEcCtD
Fluoxetine—Anorexia—Lamivudine—acquired immunodeficiency syndrome	4e-05	0.000206	CcSEcCtD
Fluoxetine—Insomnia—Saquinavir—acquired immunodeficiency syndrome	3.97e-05	0.000205	CcSEcCtD
Fluoxetine—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	3.97e-05	0.000205	CcSEcCtD
Fluoxetine—Nausea—Abacavir—acquired immunodeficiency syndrome	3.95e-05	0.000204	CcSEcCtD
Fluoxetine—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	3.94e-05	0.000204	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	3.94e-05	0.000204	CcSEcCtD
Fluoxetine—Fatigue—Ritonavir—acquired immunodeficiency syndrome	3.94e-05	0.000203	CcSEcCtD
Fluoxetine—Urticaria—Delavirdine—acquired immunodeficiency syndrome	3.92e-05	0.000203	CcSEcCtD
Fluoxetine—Asthenia—Indinavir—acquired immunodeficiency syndrome	3.92e-05	0.000202	CcSEcCtD
Fluoxetine—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	3.92e-05	0.000202	CcSEcCtD
Fluoxetine—Hypotension—Lamivudine—acquired immunodeficiency syndrome	3.92e-05	0.000202	CcSEcCtD
Fluoxetine—Somnolence—Saquinavir—acquired immunodeficiency syndrome	3.91e-05	0.000202	CcSEcCtD
Fluoxetine—Pain—Ritonavir—acquired immunodeficiency syndrome	3.9e-05	0.000202	CcSEcCtD
Fluoxetine—Constipation—Ritonavir—acquired immunodeficiency syndrome	3.9e-05	0.000202	CcSEcCtD
Fluoxetine—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	3.9e-05	0.000202	CcSEcCtD
Fluoxetine—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	3.9e-05	0.000202	CcSEcCtD
Fluoxetine—Dizziness—Zidovudine—acquired immunodeficiency syndrome	3.88e-05	0.000201	CcSEcCtD
Fluoxetine—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	3.87e-05	0.0002	CcSEcCtD
Fluoxetine—Pruritus—Indinavir—acquired immunodeficiency syndrome	3.86e-05	0.0002	CcSEcCtD
Fluoxetine—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	3.82e-05	0.000197	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	3.82e-05	0.000197	CcSEcCtD
Fluoxetine—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	3.8e-05	0.000196	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	3.79e-05	0.000196	CcSEcCtD
Fluoxetine—Insomnia—Lamivudine—acquired immunodeficiency syndrome	3.79e-05	0.000196	CcSEcCtD
Fluoxetine—Fatigue—Saquinavir—acquired immunodeficiency syndrome	3.79e-05	0.000196	CcSEcCtD
Fluoxetine—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	3.76e-05	0.000194	CcSEcCtD
Fluoxetine—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	3.76e-05	0.000194	CcSEcCtD
Fluoxetine—Constipation—Saquinavir—acquired immunodeficiency syndrome	3.76e-05	0.000194	CcSEcCtD
Fluoxetine—Pain—Saquinavir—acquired immunodeficiency syndrome	3.76e-05	0.000194	CcSEcCtD
Fluoxetine—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	3.74e-05	0.000193	CcSEcCtD
Fluoxetine—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	3.74e-05	0.000193	CcSEcCtD
Fluoxetine—Vomiting—Zidovudine—acquired immunodeficiency syndrome	3.73e-05	0.000193	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	3.73e-05	0.000193	CcSEcCtD
Fluoxetine—Somnolence—Lamivudine—acquired immunodeficiency syndrome	3.73e-05	0.000193	CcSEcCtD
Fluoxetine—Rash—Zidovudine—acquired immunodeficiency syndrome	3.7e-05	0.000191	CcSEcCtD
Fluoxetine—Asthenia—Efavirenz—acquired immunodeficiency syndrome	3.7e-05	0.000191	CcSEcCtD
Fluoxetine—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	3.7e-05	0.000191	CcSEcCtD
Fluoxetine—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	3.69e-05	0.000191	CcSEcCtD
Fluoxetine—Headache—Zidovudine—acquired immunodeficiency syndrome	3.68e-05	0.00019	CcSEcCtD
Fluoxetine—Pruritus—Efavirenz—acquired immunodeficiency syndrome	3.65e-05	0.000189	CcSEcCtD
Fluoxetine—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	3.64e-05	0.000188	CcSEcCtD
Fluoxetine—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	3.64e-05	0.000188	CcSEcCtD
Fluoxetine—Urticaria—Ritonavir—acquired immunodeficiency syndrome	3.63e-05	0.000187	CcSEcCtD
Fluoxetine—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	3.62e-05	0.000187	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	3.62e-05	0.000187	CcSEcCtD
Fluoxetine—Fatigue—Lamivudine—acquired immunodeficiency syndrome	3.61e-05	0.000187	CcSEcCtD
Fluoxetine—Dizziness—Indinavir—acquired immunodeficiency syndrome	3.61e-05	0.000187	CcSEcCtD
Fluoxetine—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	3.61e-05	0.000186	CcSEcCtD
Fluoxetine—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	3.61e-05	0.000186	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	3.59e-05	0.000186	CcSEcCtD
Fluoxetine—Constipation—Lamivudine—acquired immunodeficiency syndrome	3.58e-05	0.000185	CcSEcCtD
Fluoxetine—Pain—Lamivudine—acquired immunodeficiency syndrome	3.58e-05	0.000185	CcSEcCtD
Fluoxetine—Asthenia—Delavirdine—acquired immunodeficiency syndrome	3.54e-05	0.000183	CcSEcCtD
Fluoxetine—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	3.53e-05	0.000182	CcSEcCtD
Fluoxetine—Pruritus—Delavirdine—acquired immunodeficiency syndrome	3.49e-05	0.00018	CcSEcCtD
Fluoxetine—Urticaria—Saquinavir—acquired immunodeficiency syndrome	3.49e-05	0.00018	CcSEcCtD
Fluoxetine—Nausea—Zidovudine—acquired immunodeficiency syndrome	3.49e-05	0.00018	CcSEcCtD
Fluoxetine—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	3.47e-05	0.000179	CcSEcCtD
Fluoxetine—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	3.47e-05	0.000179	CcSEcCtD
Fluoxetine—Vomiting—Indinavir—acquired immunodeficiency syndrome	3.47e-05	0.000179	CcSEcCtD
Fluoxetine—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	3.45e-05	0.000178	CcSEcCtD
Fluoxetine—Rash—Indinavir—acquired immunodeficiency syndrome	3.44e-05	0.000178	CcSEcCtD
Fluoxetine—Dermatitis—Indinavir—acquired immunodeficiency syndrome	3.44e-05	0.000178	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	3.43e-05	0.000177	CcSEcCtD
Fluoxetine—Headache—Indinavir—acquired immunodeficiency syndrome	3.42e-05	0.000177	CcSEcCtD
Fluoxetine—Dizziness—Efavirenz—acquired immunodeficiency syndrome	3.41e-05	0.000176	CcSEcCtD
Fluoxetine—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	3.38e-05	0.000175	CcSEcCtD
Fluoxetine—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	3.36e-05	0.000174	CcSEcCtD
Fluoxetine—Urticaria—Lamivudine—acquired immunodeficiency syndrome	3.33e-05	0.000172	CcSEcCtD
Fluoxetine—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	3.31e-05	0.000171	CcSEcCtD
Fluoxetine—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	3.31e-05	0.000171	CcSEcCtD
Fluoxetine—Vomiting—Efavirenz—acquired immunodeficiency syndrome	3.28e-05	0.00017	CcSEcCtD
Fluoxetine—Asthenia—Ritonavir—acquired immunodeficiency syndrome	3.27e-05	0.000169	CcSEcCtD
Fluoxetine—Dizziness—Delavirdine—acquired immunodeficiency syndrome	3.26e-05	0.000169	CcSEcCtD
Fluoxetine—Rash—Efavirenz—acquired immunodeficiency syndrome	3.25e-05	0.000168	CcSEcCtD
Fluoxetine—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	3.25e-05	0.000168	CcSEcCtD
Fluoxetine—Nausea—Indinavir—acquired immunodeficiency syndrome	3.24e-05	0.000168	CcSEcCtD
Fluoxetine—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	3.24e-05	0.000167	CcSEcCtD
Fluoxetine—Headache—Efavirenz—acquired immunodeficiency syndrome	3.23e-05	0.000167	CcSEcCtD
Fluoxetine—Pruritus—Ritonavir—acquired immunodeficiency syndrome	3.23e-05	0.000167	CcSEcCtD
Fluoxetine—Asthenia—Saquinavir—acquired immunodeficiency syndrome	3.15e-05	0.000163	CcSEcCtD
Fluoxetine—Vomiting—Delavirdine—acquired immunodeficiency syndrome	3.14e-05	0.000162	CcSEcCtD
Fluoxetine—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	3.12e-05	0.000161	CcSEcCtD
Fluoxetine—Rash—Delavirdine—acquired immunodeficiency syndrome	3.11e-05	0.000161	CcSEcCtD
Fluoxetine—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	3.11e-05	0.000161	CcSEcCtD
Fluoxetine—Pruritus—Saquinavir—acquired immunodeficiency syndrome	3.11e-05	0.000161	CcSEcCtD
Fluoxetine—Headache—Delavirdine—acquired immunodeficiency syndrome	3.09e-05	0.00016	CcSEcCtD
Fluoxetine—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	3.09e-05	0.00016	CcSEcCtD
Fluoxetine—Nausea—Efavirenz—acquired immunodeficiency syndrome	3.06e-05	0.000158	CcSEcCtD
Fluoxetine—Dizziness—Ritonavir—acquired immunodeficiency syndrome	3.02e-05	0.000156	CcSEcCtD
Fluoxetine—Asthenia—Lamivudine—acquired immunodeficiency syndrome	3.01e-05	0.000155	CcSEcCtD
Fluoxetine—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	3.01e-05	0.000155	CcSEcCtD
Fluoxetine—Pruritus—Lamivudine—acquired immunodeficiency syndrome	2.97e-05	0.000153	CcSEcCtD
Fluoxetine—Nausea—Delavirdine—acquired immunodeficiency syndrome	2.93e-05	0.000152	CcSEcCtD
Fluoxetine—Dizziness—Saquinavir—acquired immunodeficiency syndrome	2.91e-05	0.00015	CcSEcCtD
Fluoxetine—Vomiting—Ritonavir—acquired immunodeficiency syndrome	2.9e-05	0.00015	CcSEcCtD
Fluoxetine—Rash—Ritonavir—acquired immunodeficiency syndrome	2.88e-05	0.000149	CcSEcCtD
Fluoxetine—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	2.88e-05	0.000149	CcSEcCtD
Fluoxetine—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	2.87e-05	0.000148	CcSEcCtD
Fluoxetine—Headache—Ritonavir—acquired immunodeficiency syndrome	2.86e-05	0.000148	CcSEcCtD
Fluoxetine—Vomiting—Saquinavir—acquired immunodeficiency syndrome	2.79e-05	0.000144	CcSEcCtD
Fluoxetine—Dizziness—Lamivudine—acquired immunodeficiency syndrome	2.77e-05	0.000143	CcSEcCtD
Fluoxetine—Rash—Saquinavir—acquired immunodeficiency syndrome	2.77e-05	0.000143	CcSEcCtD
Fluoxetine—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	2.77e-05	0.000143	CcSEcCtD
Fluoxetine—Headache—Saquinavir—acquired immunodeficiency syndrome	2.75e-05	0.000142	CcSEcCtD
Fluoxetine—Nausea—Ritonavir—acquired immunodeficiency syndrome	2.71e-05	0.00014	CcSEcCtD
Fluoxetine—Vomiting—Lamivudine—acquired immunodeficiency syndrome	2.66e-05	0.000138	CcSEcCtD
Fluoxetine—Rash—Lamivudine—acquired immunodeficiency syndrome	2.64e-05	0.000137	CcSEcCtD
Fluoxetine—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	2.64e-05	0.000136	CcSEcCtD
Fluoxetine—Headache—Lamivudine—acquired immunodeficiency syndrome	2.63e-05	0.000136	CcSEcCtD
Fluoxetine—Nausea—Saquinavir—acquired immunodeficiency syndrome	2.61e-05	0.000135	CcSEcCtD
Fluoxetine—Nausea—Lamivudine—acquired immunodeficiency syndrome	2.49e-05	0.000129	CcSEcCtD
